By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

An Anthem Blue Cross subscriber is suing the health insurer, alleging she was wrongfully denied coverage for Zepbound for weight management because she was no longer considered morbidly obese. Alicia ...

One company remains at the forefront of the AI frenzy, whereas the other has seen insiders dive in post-earnings.

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Eli Lilly for allegedly bribing and ...

Rising health-care costs also are once again outpacing overall inflation, according to a Mercer survey of businesses, with ...

As Trump has pressured drugmakers to lower the cost of medicines in the U.S., the pharma industry has coalesced behind a ...

While clearing up some misconceptions about her health journey, the actress, 44, reflected on the use of medicines like GLP-1 ...

Novo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes ...

CHICAGO — New research is showing certain weight loss drugs could be linked to eye related issues. A couple studies published in the Journal of the American Medical Association looks into Ozempic, ...